B+
Bull case
25%
Probability
Target price
$51.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
BEAM
Beam TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
BEAM-302 produced durable, dose-responsive biomarker effects, including total AAT above the protective threshold and an 84% reduction in Z-AAT at 60 mg, while the pivotal cohort is already dosing. The long cash runway and a potential risto-cel BLA submission add diversification.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +27.8.
What can break
BEAM-302 efficacy evidence remains based on an open-label early-stage study; interim biomarker responses may not predict pivotal, clinical or commercial success.
Momentum
17
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.00 · Bull $51.00 · Bear $16.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $51.07
Why
Momentum17 · Δ7d -8.0
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +27.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +27.8.
Contradictions & invalidation
- • BEAM-302 efficacy evidence remains based on an open-label early-stage study; interim biomarker responses may not predict pivotal, clinical or commercial success.
- • Mild-to-moderate infusion-related reactions occurred in 41% of patients, and one 60 mg Part B patient experienced transient Grade 3 ALT/AST elevations, making larger-cohort safety an important monitoring point [#IR-2026-09-08].
- • The September update largely confirmed rather than numerically improved the March dataset, and shares fell roughly 9% on September 8 as investors sought stronger incremental evidence.
Catalyst clock
2026-12-11
BEAM-302 pivotal execution becomes the next major proof point
Lead driver: Sentiment · See AI snapshot
Momentum
17
9% active weight
Current posture
7d trendSoftening
Δ7d
-8.0
Δ21d
+0.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+27.8
Δ21d
+30.9
Why this grade
Composite grade A. Momentum 17.2 / Value 41.2 / Sentiment 99.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.8B
Beta
2.12
Shares Out
103.29M
P/E (TTM) · Derived
-33.5
P/S (TTM)
48.90
P/FCF (TTM) · Derived
-7.54
Rev YoY
-94.2%
EPS YoY
+17.4%
Gross Margin
+85.7%
Op Margin
-242.3%
Net Debt
-$1.09B
Current Ratio
14.57
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data